Silgan Reports Mixed Q4, Full Year 2025 Results; Provides Modest 2026 EPS Guidance
SLGN sits 33% above its 52-week low of $36.15 on elevated volume (2.4× avg).
Summary
Silgan Holdings reported full year 2025 growth in sales, adjusted EPS, and free cash flow, but Q4 2025 adjusted EPS declined. The company provided 2026 guidance for modest adjusted EPS and free cash flow growth, with a projected Q1 2026 adjusted EPS decrease.
Key Events · Earnings and Guidance · SLGN
-
Full Year 2025 Adjusted EPS Growth
Adjusted diluted EPS increased 3% to $3.72, with net sales reaching $6.5 billion, up 11% from 2024.
-
Q4 2025 Adjusted EPS Decline
Adjusted diluted EPS for the fourth quarter decreased to $0.67 from $0.85 in Q4 2024, despite a 4% increase in net sales to $1.47 billion.
-
Strong Free Cash Flow
Full year 2025 free cash flow grew 14% to $445.2 million, exceeding the company's estimate.
-
2026 Full Year Guidance
Company projects full year 2026 adjusted diluted EPS in the range of $3.70 to $3.90 (2% growth at midpoint) and approximately $450 million in free cash flow.
Analysis · SLGN · Manufacturing
Silgan Holdings delivered a solid full year 2025, driven by strong performance in its Dispensing and Specialty Closures and Custom Containers segments, and growth in pet food markets. The company also exceeded its free cash flow estimate. However, the fourth quarter of 2025 saw a notable decline in adjusted diluted EPS compared to the prior year, primarily due to higher tax rates and other adjustments. The 2026 full-year adjusted EPS guidance indicates modest growth, while the first quarter 2026 adjusted EPS is projected to decrease, influenced by prior year inventory benefits and higher interest expenses. Investors will likely focus on the Q4 adjusted EPS decline and the conservative Q1 2026 outlook, despite the overall positive full-year 2025 performance and strategic progress.
At the time of this filing, SLGN was trading at $47.97 on NYSE in the Manufacturing sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $36.15 to $57.04. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.